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Type 2 diabetes is a major global health problem. It is also a risk factor for the onset of 
cardiovascular diseases, the current leading cause of global mortality. The first part of this 
mini-review describes hyperglycemia-induced cellular alterations and its effects on cardiac 
function. In particular, we emphasize the role of hyperglycemia-induced oxidative stress in the 
activation of non-oxidative glucose pathways (NOGPs), that may contribute to cardiac 
pathology. For the second part, we evaluate the utility of benfotiamine (a vitamin B1 
derivative) in treating diabetes-related cardiac pathology.  The focus is on its role in activating 
the pentose phosphate pathway, which may reduce flux though the NOGPs.  A possible role 
for benfotiamine in activating pro-survival signaling and reducing cell death in the heart is also 
described.  We also discuss benfotiamine’s potential cardioprotective role in preventing the 
diabetic cardiomyopathy, treating myocardial infarction and maintaining the viability of 
cardiac progenitor cells. These findings warrant further investigation into the therapeutic 
potential of benfotiamine in treating diabetes-related cardiac complications.  
  
 






In 2011 the global prevalence of diabetes 
mellitus was approximately 366 million, with this 
figure expected to rise to 552 million by the year 2030 
(Whiting et al. 2011). Diabetes and its complications 
place an immense financial burden upon individuals 
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and economies, hindering development in low- and 
middle-income countries. During 2010 11.6% of the 
total global healthcare expenditure was attributed to 
diabetes (Colagiuri 2010). Moreover, this condition is 
associated with a significantly higher incidence of 
cardiovascular diseases (Fox 2010), the leading cause 
of global mortality. 
Type 2 diabetes comprises the majority of 
reported diabetes cases and elicits a plethora of 
metabolic perturbations that are well-described, 
including hyperinsulinemia, hyperlipidemia and 
hyperglycemia (Calles-Escandon et al. 1999). For the 
purposes of this mini-review, we will focus on the 
effects of hyperglycemia with particular emphasis on 
its impact on the heart.  Moreover, the role of 
benfotiamine (BFT) in counteracting these effects will 
also be assessed. 
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Damaging effects of hyperglycemia on cardiac 
function 
With type 2 diabetes, reduced responsiveness to insulin 
and greater plasma glucose concentrations lead to 
increased intracellular glucose levels in several cell 
types. The resulting increase in glycolysis and 
overproduction of NADH and FADH2 (in citric acid 
cycle) lead to the enhanced generation of reactive 
oxygen species (ROS) - specifically superoxide - by the 
electron transport chain (Du et al. 2000). An emerging 
paradigm proposed by Brownlee (2001) describes 
mitochondrial superoxide overproduction as the cause 
of a number of hyperglycemia-induced alterations 
(Figure 1). Here superoxide is proposed to cause DNA 
damage and subsequent activation of poly-ADP-ribose 
polymerase (PARP) as a restorative mechanism 
(Graziani & Szabó 2005). However, PARP activation is 
associated with inhibition of the key glycolytic enzyme 
glyceraldehyde–3-phosphate dehydrogenase (GAPDH) 
(Du et al. 2003). This in turn leads to the build-up of 
upstream glycolytic metabolites and increased 
diversion into non-oxidative glucose pathways 
(NOGPs), with maladaptive consequences (Brownlee 
2005). 
NOGP activation includes increased flux 
through the polyol pathway, an elevation of advanced 
glycation end-product (AGE) formation, activation of 
protein kinase C (PKC) isoforms, and greater flux 
through the polyol and hexosamine biosynthetic 
pathways (HBP). For example, we recently reported 
increased HBP activation in leukocytes isolated from 
pre-diabetic and diabetic patients (Springhorn et al. 
2012) and also greater activation of all four NOGPs in 
the heart in response to acute hyperglycemia (Mapanga 
et al. 2014).  
Excessive NOGP flux is associated with a 
range of harmful alterations that vary according to cell 
type.  For example, hyperglycemia in cardiac cells and 
the resulting increase in NOGP activation are proposed 
to contribute to systolic and diastolic dysfunction 
(Poornima et al. 2006). Here increased HBP flux leads 
to post-translational modification of proteins that may 
impair relaxation of the heart (Clark et al. 2003) and 
cause cell death (Fiordaliso et al. 2001). This is 
supported by studies from our laboratory, 
demonstrating that cardiac cells cultured under 
hyperglycemic conditions display elevated oxidative 
stress, enhanced HBP activation, and increased cell 
death (Rajamani & Essop 2011). These findings were 
confirmed in heart tissues isolated from a rat model of 
diet-induced insulin resistance (Rajamani et al. 2011).  
Excessive AGE formation is associated with cross-
linking of collagen (Candido et al. 2003) and ryanodine 
receptors (Bidasee et al. 2003) that may reduce 
contractility and increase ventricular stiffness 
(Herrmann et al. 2003). Furthermore, high flux though 
the polyol pathway elevates oxidative stress (Tang et al. 
2010) and promotes cardiomyocyte apoptosis (Galvez 
et al. 2003), while enhanced PKC activation can lead to 
cardiac hypertrophy, impaired relaxation and increased 
ventricular stiffness (Wakasaki et al. 1997; Scherer et 
al. 2006).  Thus hyperglycemia-induced perturbations 
are associated with oxidative stress and NOGP 
induction that contribute to myocardial cell death and 
impaired heart function.  Together such alterations can 
contribute to the diabetic cardiomyopathy, that refers to 
diabetes-related cardiac dysfunction in the absence of 
coronary artery disease or hypertension (Boudina & 
Abel 2007).  
However, the effects of hyperglycemia on the 
heart are not limited to the development of the diabetic 
cardiomyopathy. By promoting atherosclerosis, 
hyperglycemia also increases the likelihood of 
myocardial infarction in diabetic patients (Fowler 
2008). Moreover, hyperglycemia per se may exert 
direct effects on the heart. For instance, the presence of 
hyperglycemia during myocardial infarction is 
associated with increased mortality (Koracevic et al. 
2006). This was confirmed by our recent work 
demonstrating coordinate induction of NOGPs in 
response to acute hyperglycemia and resulting in 
increased oxidative stress and cell death together with 
impaired cardiac function following 
ischemia-reperfusion (Mapanga et al. 2014).  Our data 
therefore support a significant pathophysiologic role for 
such NOGP induction within the context of ischemia-
reperfusion under hyperglycemic conditions.  
A third context where the effects of hyperglycemia on 
the heart are visible is with cardiogenesis. For example, 
a recent study found decreased abundance and 
proliferation of cardiac progenitor cells in the hearts of 
diabetic mice as well as an increase in AGEs.  Thus the 
damaging effects of hyperglycemia are compounded by 
its impairment of the heart’s already-limited 
regenerative capacity (Katare et al. 2013).  To 
summarize, hyperglycemia leads to NOGP activation 
and pathological alterations that can blunt the heart’s 
function, induce myocardial damage and impair cardiac 
regeneration.  This paradigm therefore allows for the 
evaluation of novel therapeutic approaches to limit 
NOGP activation under these conditions, e.g. by 
stimulation of the pentose phosphate pathway (PPP). 
 
 
Therapeutic potential of the pentose phosphate 
pathway 
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The PPP is well-known for its role in 
producing NADPH and ribose 5-phosphate, essential 
for regulating intracellular redox balance and DNA 
repair. However, it plays important additional roles in 
preventing apoptosis and promoting angiogenesis, that 
are linked to glucose 6-phosphate dehydrogenase 
(G6PD) (Riganti et al. 2012). 
G6PD is the first and rate-limiting enzyme of the PPP 
and catalyzes a reaction that generates NADPH (Figure 
2). NADPH is a key regulator of intracellular redox 
balance, essential in generating anti-oxidant capacity as 
well producing ROS.  The main components of the 
anti-oxidant machinery, namely the glutathione system, 
catalase and superoxide dismutase, require NADPH to 
function. However, NADPH is also needed for ROS 









Fig. 1.  
Unifying mechanism of hyperglycemia-induced cellular alterations. Under hyperglycemic conditions, mitochondrial 
superoxide overproduction leads to DNA damage, PARP activation and GAPDH inhibition. This in turn causes a build-up of 
upstream glycolytic metabolites and excessive flux through non-oxidative glucose pathways. Increased flux through the PKC, 
HBP, polyol and AGE pathways causes a range of pathological alterations that vary according to cell type. AGE: advanced 
glycation endproducts, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, HBP: hexosamine biosynthetic pathway, O2-: 
superoxide, PARP: poly(ADP-ribose) polymerase, PKC: protein kinase C. 
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Figure 2: The pentose phosphate pathway in glucose metabolism. Benfotiamine administration leads to increased 
transketolase and glucose 6-phosphate dehydrogenase activity, thereby enhancing flux of glycolytic metabolites into the 
pentose phosphate pathway. This increases the production of ribose 5-phosphate and NADPH that are used in DNA repair and 
regulating redox balance. 1,3-bis-PGly: 1,3-diphosphoglycerate, 3-PGra: glyceraldehyde 3-P, 6-PGcl: 6-P gluconolactone, 
6-PGlt: 6-P gluconate, α-KGDH: α-ketoglutarate dehydrogenase, Ery4-P: erythrosine 4-P, Fru6-P: fructose 6-P, G6PD: glucose 
6-phosphate dehydrogenase, Glu6-P: glucose 6-P, Rib5-P: ribose 5-P, Ru5-P: ribose 5-P, Seh7-P: sedoheptulose 7-P, Gra3-P: 
glyceraldehyde 3-P, PDH: pyruvate dehydrogenase, TK: transketolase, Xlu5-P: xylulose 5-P. 
 
 
NADPH-oxidase (NOX) (Zhao et al. 2012). Therefore 
the effects of increasing NADPH production in the 
heart via G6PD activation are controversial. For 
example, G6PD inhibition in rat cardiomyocytes 
increased oxidative stress and contractile dysfunction 
(Jain et al. 2003), suggesting that NADPH opposes 
oxidative stress. By contrast, upregulation of G6PD in a 
rat model of type 2 diabetes was associated with greater 
NADPH generation, increased NOX-catalyzed 
superoxide production and diminished anti-oxidant 
capacity in the heart (Serpillon et al. 2009).  This 
suggests that activating NADPH production in the heart 
as a protective strategy may represent a ‘’double-edged 
sword’’ since this may also promote oxidative stress.  
Further investigations are therefore needed to better 
understand the specific circumstances under which 
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Fig. 3.  
Two major pro-survival pathways in the heart. A) The PI3K/Akt signaling pathway can be activated by upstream 
regulators, e.g. adenosine.  Adenosine binding to its receptor causes PI3K to phosphorylate PIP2 to form PIP3, followed 
by Akt and PDK recruitment to the  plasma membrane – in close proximity.  PDK phosphorylates and activates Akt that 
can prevent  apoptosis by phosphorylating various downstream targets including Bad, eNOS, Pim-1, GSK-3 and  FOXO. 
Note: VEGF2 and VEGFR2 may also potentially feed into this pathway. B) The JAK/STAT pathway can be triggered by 
an upstream modulator, e.g. IL-6. IL-6 binding to its receptor recruits two gp130 molecules with associated JAK  
proteins.  JAK proteins can auto-phosphorylate itself and also the gp130 molecules, creating docking sites for STAT 
proteins to bind.  Once bound,  STATs become phosphorylated before translocating into the nucleus and regulating 
expression of cardioprotective factors.  eNOS: endothelial nitric oxide synthase, FOXO: forkhead box O, GSK: glycogen 
synthase kinase, Gp130: glycoprotein 130, IL-6: interleukin 6, PDK: 3-phosphoinositide-dependent protein kinase, PI3K: 
phosphatidylinositol 3-kinase, STAT: signal transducer and activator of transcription, VEGF: vascular endothelial growth 
factor, VEGFR2: vascular endothelial growth factor receptor 2. 
Benfotiamine and hyperglycemia-induced cardiac pathology 
 
10  J. Afr. Ass. Physiol. Sci. 2 (1): 2014 Kirsty-Lee et al 
 
 
In addition to its role in regulating redox balance, 
G6PD activation is also associated with pro-survival 
signaling, e.g. to prevent apoptosis and promote 
angiogenesis by activation of vascular endothelial 
growth factor receptor 2 (VEGFR2) and Akt (Zhang et 
al. 2014). This notion is supported by several lines of 
evidence.  Firstly, Jain et al. (2003) demonstrated that 
stimulation of G6PD activity in response to increased 
oxidative stress resulted in its translocation to the 
plasma membrane.  Moreover, G6PD is also necessary 
for phosphorylation and activation of VEGFR2, Akt 




VEGF2/Akt/eNOS signaling resulting in stimulation of 
angiogenesis (refer Figure 3A for some basic 
contextualization of these modulators) (Leopold et al. 
2003).  The activation of the VEGFR2/Akt signaling 
cascade is associated with increased levels of pAkt, 
Pim-1, pBad and Bcl-2 and reduced apoptosis (Katare 
et al. 2010). Further evidence for the involvement of 
G6PD in stimulating angiogenesis and preventing 
apoptosis was provided by partially G6PD-deficient 
mice that displayed impaired angiogenesis (Leopold et 
al. 2003) and increased myocardial dysfunction 
following ischemia-reperfusion (Jain et al. 2003). Thus 
increasing G6PD activity and promoting VEGFR2/Akt 
signaling may represent an effective cardioprotective 
strategy within the context of hyperglycemia. 
 
Benfotiamine 
BFT is one of a number of thiamine (vitamin B1) 
derivatives investigated for therapeutic use (Figure  
 
4). After allithiamine (a naturally-occurring 
thiamine derivative) was discovered in Japan (Fujiwara 
et al. 1954), researchers synthesized a group of 
additional thiamine derivatives with improved 
bioavailability. They subsequently proceeded to assess 
the value of such compounds in treating various 
diseases (Shimazono & Katsura 1965).  
BFT, or S-benzoylthiamine O-monophosphate, 
has primarily been investigated as a treatment for 





PPP flux, it can shunt glycolytic metabolites 
away from the NOGPs and hence attenuate the negative 
downstream consequences previously discussed 
(Berrone et al. 2006; Du et al. 2008).  BFT 
administration is linked to roles in preventing the 
diabetic cardiomyopathy, treating myocardial 
infarction, and maintaining the function and number of 
cardiac progenitor cells under hyperglycemic 
conditions. 
 
Preventing diabetic cardiomyopathy 
BFT’s ability to treat the diabetic 
cardiomyopathy was tested in three studies. Here 
streptozotocin-induced diabetic mice treated with BFT 
for six weeks displayed attenuated collagen, 
methylglyoxal (an AGE pathway intermediate), AGE 
receptor and methylglyoxal-derived AGE formation in 
the heart compared to untreated diabetic rats (Ma et al. 
2009).  Such findings were complemented by 
experiments in isolated cardiomyocytes where 
methylglyoxal-derived AGEs were associated with 
cardiomyocyte dysfunction, secondary to mitochondrial 
Fig. 4.  The chemical structure of thiamine and benfotiamine. Benfotiamine is a benzoylated derivative of the 
phosphorylated version of thiamine. 
Benfotiamine and hyperglycemia-induced cardiac pathology 
 
11  J. Afr. Ass. Physiol. Sci. 2 (1): 2014 Kirsty-Lee et al 
 
membrane potential depolarization and decreased 
glycogen synthase kinase (GSK-3β) (Ma et al. 2009).  
In support, others evaluated the effects of two weeks of 
BFT treatment on diabetes-induced heart dysfunction 
and found that it attenuated oxidative stress and 
counteracted diabetes-induced contractile dysfunction 
(Ceylan-Isik et al. 2006).  
In order to investigate the efficacy of long-term 
BFT supplementation in preventing diabetic 
cardiomyopathy, Katare et al. (2010A) employed two 
diabetic mouse models. Here streptozotocin-induced 
and leptin receptor-deficient db/db mice were 
supplemented with benfotiamine for 8 and 16 weeks, 
respectively. Hearts of untreated diabetic mice showed 
reduced transketolase (TK), G6PD and GAPDH 
activities, while ROS production and cardiomyocyte 
apoptosis were elevated. The progression of diabetic 
cardiomyopathy was also associated with decreased 
phosphorylation of signal transducer and activator of 
transcription 3 (STAT3), Akt, eNOS, Forkhead box O 
(FOXO) and Bad, in addition to lower levels of proviral 
integration site of Moloney murine leukemia virus 
(Pim-1) and Bcl-2. Phosphorylation of these proteins is 
associated with the prevention of apoptosis (refer 
Figure 3B for some basic contextualization of these 
modulators).  Such perturbations were all prevented by 
BFT treatment.  These findings suggest that, in addition 
to inducing protection by activating the PPP and 
reducing NOGP flux, BFT may also induce protection 
by activating pro-survival via Akt and Pim-1.  
 
Treating myocardial infarction 
Hyperglycemia is common during myocardial 
infarction. Chronic hyperglycemia is characteristic of 
diabetes, a condition that commonly manifests with 
myocardial infarction. Furthermore, acute 
hyperglycemia occurs during myocardial infarction in 
non-diabetic individuals as result of sympathetic 
nervous system activation in response to stress. Since 
the presence of hyperglycemia during myocardial 
infarction is associated with increased mortality 
(Koracevic et al. 2006), two recent studies investigated 
the role of BFT in treating myocardial infarction (with 
and without hyperglycemia). 
A study by Katare et al. (2010B) investigated 
long-term BFT supplementation in streptozotocin-
treated mice and found the diabetic mice displayed 
increased apoptosis, more oxidative stress, less 
reparative angiogenesis, impaired VEGFR2/Akt/Pim-1 
signaling, and lower functional recovery and survival 
than their non-diabetic counterparts.  BFT 
supplementation restored VEGFR2/Alt/Pim-1 
signaling, increased levels of pAkt, Pim-1, pBad and 
Bcl-2, decreased apoptosis, and counteracted the 
above-mentioned effects of diabetes.  These findings 
were complemented by experiments in isolated 
cardiomyocytes where BFT treatment preserved 
VEGFR2/Akt/Pim-1 signaling under hypoxic and 
hyperglycemic conditions (Katare et al. 2010B). 
Secondly, a study by our group found that 
acute BFT administration was beneficial in attenuating 
hyperglycemia-induced perturbations, preventing 
oxidative stress and attenuating cell death in the rat 
heart.  Here BFT administration blunted 
hyperglycemia-mediated NOGP activation, thereby 
activating beneficial downstream effects, more 
specifically a reduction in infarct size and an 
improvement in functional recovery following ischemia 
and reperfusion (Mapanga et al. 2014). Our data also 
revealed that BFT provided cardioprotection under 
normoglycemic conditions and we propose that this 
may occur via the Akt/Pim-1 pro-survival signaling.  
However, further studies are required to confirm this 
interesting proposition. 
In addition to preventing hyperglycemia-
induced cellular alterations and protecting cardiac cells 
from apoptosis exacerbated by hyperglycemia, BFT can 




A recent study demonstrated decreased 
abundance and proliferation of cardiac progenitor cells 
in diabetic mice (Katare et al. 2013). Here isolated 
cardiac progenitor cells exhibited impaired activity of 
TK and G6PD, increased levels of superoxide and 
AGEs, and attenuated Akt/Pim-1/Bcl-2 signaling. 
Human and mouse cardiac progenitor cells cultured in 
high glucose showed similar perturbations and such 
changes were associated with increased apoptosis. 
However, BFT administration restored PPP enzyme 
activity and cardiac progenitor cell availability and 
function in vitro and in vivo (Katare et al. 2013). 
 
CONCLUSION 
Hyperglycemia induces cellular alterations that 
contribute to a range of cardiac pathologies. 
Experimental studies suggest that BFT shows promise 
in counteracting these alterations and opens up 
possibilities for the treatment of the diabetic 
cardiomyopathy, myocardial infarction and impaired 
cardiogenesis typically found with diabetes. The the 
therapeutic potential of BFT in treating diabetes-related 
cardiac complications therefore warrants further 
investigation. 
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